Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 AZD3514 in Japanese Patients With Metastatic Castration-Resistant Prostate Cancer
jRCT2080221560Phase 1
- Sponsor
- AstraZeneca
- Start
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AZD3514 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by AstraZeneca.
02
Drugs
AZD3514
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on jRCT2080221560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221560.